Brofaromine (BioDeep_00000837752)
代谢物信息卡片
Brofaromine
化学式: C14H16BrNO2 (309.0364336)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: COC1=CC(=C2C(=C1)C=C(O2)C3CCNCC3)Br
InChI: InChI=1S/C14H16BrNO2/c1-17-11-6-10-7-13(9-2-4-16-5-3-9)18-14(10)12(15)8-11/h6-9,16H,2-5H2,1H3
描述信息
D004791 - Enzyme Inhibitors > D008996 - Monoamine Oxidase Inhibitors
C471 - Enzyme Inhibitor > C667 - Monoamine Oxidase Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Marco Antonioli, Joanna Rybka, Livia A Carvalho. Neuroimmune endocrine effects of antidepressants.
Neuropsychiatric disease and treatment.
2012; 8(?):65-83. doi:
10.2147/ndt.s16409. [PMID: 22347798] - Marios P Hadjicharalambous, Liam P Kilduff, Yannis P Pitsiladis. Brain serotonergic and dopaminergic modulators, perceptual responses and endurance exercise performance following caffeine co-ingested with a high fat meal in trained humans.
Journal of the International Society of Sports Nutrition.
2010 May; 7(?):22. doi:
10.1186/1550-2783-7-22. [PMID: 20507554] - Marios Hadjicharalambous, Liam P Kilduff, Yannis P Pitsiladis. Brain serotonin and dopamine modulators, perceptual responses and endurance performance during exercise in the heat following creatine supplementation.
Journal of the International Society of Sports Nutrition.
2008 Sep; 5(?):14. doi:
10.1186/1550-2783-5-14. [PMID: 18826587] - André Boland, Jean Gérardy, Danielle Mossay, Vincent Seutin. Pre- and post-treatment with pirlindole and dehydropirlindole protects cultured brain cells against nitric oxide-induced death.
European journal of pharmacology.
2003 Apr; 466(1-2):21-30. doi:
10.1016/s0014-2999(03)01539-5. [PMID: 12679138] - L J Urichuk, K Allison, A Holt, A J Greenshaw, G B Baker. Comparison of neurochemical effects of the monoamine oxidase inhibitors phenelzine, moclobemide and brofaromine in the rat after short- and long-term administration.
Journal of affective disorders.
2000 May; 58(2):135-44. doi:
10.1016/s0165-0327(99)00105-6. [PMID: 10781703] - R Uebelhack, L Franke, H J Schewe. Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava).
Pharmacopsychiatry.
1998 Sep; 31(5):187-92. doi:
10.1055/s-2007-979325. [PMID: 9832350] - B R Slaap, I M van Vliet, H G Westenberg, J A Den Boer. MHPG and heart rate as correlates of nonresponse to drug therapy in panic disorder patients. A preliminary report.
Psychopharmacology.
1996 Oct; 127(4):353-8. doi:
10.1007/s002130050097. [PMID: 8923571] - J Zeeh, L Fuchs, W Bergmann, K H Antonin, F Degel, P Bieck, D Platt. Influence of age, frailty and liver function on the pharmacokinetics of brofaromine.
European journal of clinical pharmacology.
1996; 49(5):387-91. doi:
10.1007/bf00203783. [PMID: 8866634] - T Fahlén, H L Nilsson, K Borg, M Humble, U Pauli. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study.
Acta psychiatrica Scandinavica.
1995 Nov; 92(5):351-8. doi:
10.1111/j.1600-0447.1995.tb09596.x. [PMID: 8619339] - B A Davis, S H Kennedy, J D'Souza, D A Durden, D S Goldbloom, A A Boulton. Correlations of plasma and urinary phenylacetic acid and phenylethylamine concentrations with eating behavior and mood rating scores in brofaromine-treated women with bulimia nervosa.
Journal of psychiatry & neuroscience : JPN.
1994 Jul; 19(4):282-8. doi:
. [PMID: 7918350] - C H Gleiter, B Mühlbauer, R M Schulz, E Nilsson, K H Antonin, P R Bieck. Monoamine oxidase inhibition by the MAO-A inhibitors brofaromine and clorgyline in healthy volunteers.
Journal of neural transmission. General section.
1994; 95(3):241-5. doi:
10.1007/bf01271570. [PMID: 7865179] - S H Kennedy, B A Davis, G M Brown, C G Ford, J d'Souza. Effects of chronic brofaromine administration on biogenic amines including sulphatoxymelatonin and acid metabolites in patients with bulimia nervosa.
Neurochemical research.
1993 Dec; 18(12):1281-5. doi:
10.1007/bf00975048. [PMID: 7505890] - B A Davis, S H Kennedy, D A Durden, J D'Souza, D S Goldbloom, A A Boulton. The effect of the MAO-A selective inhibitor brofaromine on the plasma and urine concentrations of some biogenic amines and their acidic metabolites in bulimia nervosa.
Progress in neuro-psychopharmacology & biological psychiatry.
1993 Sep; 17(5):747-63. doi:
10.1016/0278-5846(93)90057-y. [PMID: 7504824] - P H Degen, J M Cardot, C Czendlik, W Dieterle. Influence of food on the disposition of the monoamine oxidase-A inhibitor brofaromine in healthy volunteers.
Biopharmaceutics & drug disposition.
1993 Apr; 14(3):209-15. doi:
10.1002/bdd.2510140304. [PMID: 8490109] - M Jedrychowski, N Feifel, P R Bieck, E K Schmidt. Metabolism of the new MAO-A inhibitor brofaromine in poor and extensive metabolizers of debrisoquine.
Journal of pharmaceutical and biomedical analysis.
1993 Mar; 11(3):251-5. doi:
10.1016/0731-7085(93)80205-f. [PMID: 8518326] - G Lavian, J P Finberg, M B Youdim. The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine.
Clinical neuropharmacology.
1993; 16 Suppl 2(?):S1-7. doi:
NULL. [PMID: 8313392] - N Feifel, K Kucher, L Fuchs, M Jedrychowski, E Schmidt, K H Antonin, P R Bieck, C H Gleiter. Role of cytochrome P4502D6 in the metabolism of brofaromine. A new selective MAO-A inhibitor.
European journal of clinical pharmacology.
1993; 45(3):265-9. doi:
10.1007/bf00315394. [PMID: 8276052] - P Celada, J Pérez, E Alvarez, F Artigas. Monoamine oxidase inhibitors phenelzine and brofaromine increase plasma serotonin and decrease 5-hydroxyindoleacetic acid in patients with major depression: relationship to clinical improvement.
Journal of clinical psychopharmacology.
1992 Oct; 12(5):309-15. doi:
. [PMID: 1282522] - I M van Vliet, J A den Boer, H G Westenberg. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology.
1992 Mar; 2(1):21-9. doi:
10.1016/0924-977x(92)90032-4. [PMID: 1638170] - M C Anderson, P C Waldmeier, K F Tipton. The inhibition of monoamine oxidase by brofaromine.
Biochemical pharmacology.
1991 Jun; 41(12):1871-7. doi:
10.1016/0006-2952(91)90126-p. [PMID: 2039542] - J Fritze, T Becker, V Ziegler, G Laux, P Riederer. Brofaromine (CGP 11 305 A) in treatment of depression: biological estimation of plasma concentrations.
Pharmacopsychiatry.
1990 May; 23(3):131-4. doi:
10.1055/s-2007-1014495. [PMID: 2374771] - J Fritze, T Becker, V Ziegler, G Laux, P Bieck, E Sofic, P Riederer. Brofaromine (CGP 11 305 A): estimation of plasma concentrations by a biologic technique as compared to liquid chromatography.
Journal of neural transmission. Supplementum.
1990; 32(?):197-201. doi:
10.1007/978-3-7091-9113-2_29. [PMID: 2089091] - G Laux, W Classen, E Sofic, T Becker, P Riederer, K P Lesch, M Struck, H Beckmann. Clinical, biochemical and psychometric findings with the new MAO-A-inhibitors moclobemide and brofaromine in patients with major depressive disorder.
Journal of neural transmission. Supplementum.
1990; 32(?):189-95. doi:
10.1007/978-3-7091-9113-2_28. [PMID: 2089089] - W Schneider, B Keller, P H Degen. Determination of the new monoamine oxidase inhibitor brofaromine and its major metabolite in biological material by gas chromatography with electron-capture detection.
Journal of chromatography.
1989 Mar; 488(1):275-82. doi:
10.1016/s0378-4347(00)82952-7. [PMID: 2715286] - P R Bieck, L Firkusny, C Schick, K H Antonin, E Nilsson, R Schulz, M Schwenk, H Wollmann. Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers.
Clinical pharmacology and therapeutics.
1989 Mar; 45(3):260-9. doi:
10.1038/clpt.1989.26. [PMID: 2920501] - C Horne, E Mutschler. Quantitative determination of brofaromin in human plasma after high performance liquid chromatographic separation.
Archiv der Pharmazie.
1988 Jun; 321(6):359-61. doi:
10.1002/ardp.19883210613. [PMID: 3178436] - P R Bieck, K H Antonin, R Balon, G Oxenkrug. Effect of brofaromine and pargyline on human plasma melatonin concentrations.
Progress in neuro-psychopharmacology & biological psychiatry.
1988; 12(1):93-101. doi:
10.1016/0278-5846(88)90064-4. [PMID: 3363166] - A Steiger, F Holsboer, O Benkert. Effects of brofaremine (CGP 11 305A), a short-acting, reversible, and selective inhibitor of MAO-A on sleep, nocturnal penile tumescence and nocturnal hormonal secretion in three healthy volunteers.
Psychopharmacology.
1987; 92(1):110-4. doi:
10.1007/bf00215489. [PMID: 3110820] - P C Waldmeier, K H Antonin, J J Feldtrauer, C Grunenwald, E Paul, J Lauber, P Bieck. Urinary excretion of O-methylated catecholamines, tyramine and phenyl-ethylamine by volunteers treated with tranylcypromine and CGP 11305 A.
European journal of clinical pharmacology.
1983; 25(3):361-8. doi:
10.1007/bf01037949. [PMID: 6628524]
